|
Patient
characteristics and immunophenotyping of malignant gammopathies
for expression of MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1
on tumor cellsa.
|
Diagnosis
|
Patient
No.
|
Age
|
Stage
|
Cytogenetics
|
B2M
(mg/l)
|
Albumin
(g/dl)
|
LDH
(U/l)
|
MAGE-A1
(MAb MA454)
|
MAGE-A3
(MAb M3H67)
|
MAGE-A4
(MAb 57B)
|
CT-7
(MAb CT7-33)
|
NY-ESO-1
(MAb ES121)
|
|
Myeloma
|
1
|
70
|
III
|
normal
|
9.4
|
4.1
|
ND
|
1+
|
3+
|
2+
|
4+
|
-
|
|
2
|
77
|
III
|
t13:14, 11q14
|
1.3
|
3.7
|
ND
|
focal
|
focal
|
-
|
-
|
-
|
|
3
|
41
|
II
|
normal
|
1.8
|
4.9
|
140
|
-
|
-
|
-
|
1+
|
-
|
|
4
|
71
|
III
|
trisomy 11
|
6.7
|
3.1
|
177
|
-
|
2+
|
-
|
4+
|
-
|
|
5
|
63
|
III
|
13q-, trisomy 11
|
5.2
|
4.1
|
104
|
-
|
-
|
-
|
focal
|
-
|
|
6
|
57
|
III
|
13q-
|
NMA
|
5.4
|
179
|
-
|
1+
|
-
|
2+
|
-
|
|
7
|
73
|
III
|
trisomy 11
|
4.9
|
3.6
|
ND
|
-
|
-
|
-
|
1+
|
-
|
|
8
|
53
|
II
|
ND
|
NMA
|
4.2
|
130
|
-
|
-
|
-
|
-
|
-
|
|
9
|
70
|
III
|
normal
|
7.5
|
2.8
|
107
|
-
|
2+
|
-
|
3+
|
1+
|
|
10
|
73
|
I
|
normal
|
1.4
|
3.6
|
95
|
-
|
-
|
-
|
1+
|
-
|
|
11
|
57
|
III
|
normal
|
7.8
|
2.7
|
ND
|
-
|
-
|
-
|
-
|
-
|
|
12
|
42
|
III
|
NA
|
3.5
|
4
|
196
|
4+
|
2+
|
-
|
focal
|
focal
|
|
13
|
79
|
IIIB
|
normal
|
4.7
|
4.3
|
268
|
-
|
-
|
-
|
-
|
1+
|
|
Extramedullary
plasmacytoma
|
14
|
67
|
|
trisomy 11
|
ND
|
4
|
122
|
2+
|
4+
|
4+
|
4+
|
focal
|
|
15
|
52
|
|
normal
|
NMA
|
4.5
|
140
|
1+
|
4+
|
focal
|
4+
|
-
|
|
16
|
68
|
|
ND
|
1.3
|
ND
|
ND
|
-
|
focal
|
-
|
-
|
-
|
|
17
|
64
|
|
ND
|
2.2
|
3.9
|
ND
|
2+
|
3+
|
2+
|
3+
|
focal
|
|
Plasmacytoma
|
18
|
58
|
|
ND
|
ND
|
3.5
|
ND
|
focal
|
3+
|
focal
|
4+
|
focal
|
|
19
|
65
|
|
ND
|
NMA
|
4.3
|
184
|
-
|
-
|
-
|
focal
|
-
|
|
20
|
72
|
|
normal
|
2.1
|
4.5
|
ND
|
-
|
focal
|
-
|
1+
|
-
|
|
21
|
55
|
|
NA
|
5.7
|
4
|
99
|
-
|
-
|
-
|
-
|
focal
|
|
22
|
56
|
|
ND
|
NMA
|
4.5
|
ND
|
-
|
-
|
focal
|
4+
|
-
|
|
23
|
44
|
|
ND
|
ND
|
4.6
|
120
|
-
|
-
|
-
|
3
|
focal
|
|
24
|
83
|
|
NA
|
10.2
|
4.8
|
151
|
-
|
-
|
-
|
focal
|
-
|
|
25
|
53
|
|
ND
|
3.7
|
ND
|
ND
|
-
|
-
|
-
|
1+
|
-
|
|
26
|
71
|
|
ND
|
3.5
|
ND
|
ND
|
-
|
-
|
-
|
3+
|
focal
|
|
27
|
67
|
|
ND
|
8.1
|
ND
|
ND
|
-
|
3+
|
-
|
4+
|
-
|
|
28
|
44
|
|
normal
|
4
|
ND
|
ND
|
-
|
focal
|
-
|
focal
|
-
|
|
29
|
71
|
|
ND
|
ND
|
3.7
|
88
|
-
|
-
|
-
|
4+
|
-
|
|
Total
number of patients with CT antigen positive tumor cells
(% positive)
|
7 (24%)
|
14 (48%)
|
6 (21%)
|
23 (79%)
|
8 (27%)
|
|
Total
number of patients with CT antigen positivity in >50%
tumor cells (% positive)
|
1 (3%)
|
6 (21%)
|
1 (3%)
|
11 (38%)
|
0 (0%)
|
aGrading
for expression of CT antigens on tumor cells: focal, <5%; 1+,
5-24%; 2+, 25-49%; 3+, 50-74%; 4+, 75-100%. Abbreviations: NA,
not analyzable; ND, not done; NMA, no measurable amount; B2M,
serum beta-2-microglobulin; LDH, serum lactate dehydrogenase.
|
